The preliminary results of the phase I/II study evaluating the safety, tolerability, and preliminary efficacy of 9MW2821, a Nectin-4-targeting antibody-drug conjugate (ADC)
Nexusflow raised $10.6 million as part of a seed round led by Point72 Ventures, with participation from Fusion Fund and several artificial intelligence (AI) luminaries.